SYBX Bathi resik saben saham sajrone 12 wulan pungkasan Synlogic, Inc.

The efficiency of Synlogic, Inc. (SYBX) is based on the ability of modified bacteria to process toxins, which is critical for the treatment of phenylketonuria. This 12-month net income per share chart demonstrates current profitability, where the value of -0.27 serves as the current metric. The absence of cyclical dependence makes the company a hostage to the availability of venture capital, and the freezing of core programs has effectively destroyed its market advantage.

This indicator determines the investment stability of the issuer through the lens of real income per share of capital. The metric is calculated by dividing the total annual net income by the total number of shares, excluding the impact of equity dilution. By analyzing the current annual net income per share, an investor can observe the dynamics of operational efficiency. For Synlogic, Inc. (SYBX), this parameter reflects the cost of developing "living medicines" for gastrointestinal therapy. The stability of the trend confirms the biotech company's ability to monetize the treatment of rare metabolic disorders.